Johnson & Johnson

Last price update: 07 Oct 24 23:00 GMT

Price:
$159.53
Open:
$160.25
Previous close:
$160.29
Day's range:
$159.22 - $160.86
Year's range:
$143.13 - $168.85
Net Income per Share:
6.60
Price-to-Earnings ratio:
24.17
52-week Price Range:
$162.50
Volume:
$3,006,647.00
Average volume:
$6,606,623.00

Company profile for Johnson & Johnson

Johnson & Johnson logo

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company’s Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Stock exchanges:
NYSE
Sector:
Healthcare
Industries:
Drug Manufacturers
Ticker:
JNJ
CIK:
0000200406
ISIN:
US4781601046
Website:
https://www.jnj.com
Phone:
732 524 0400
Origin:
United States
Employees:
141,700

Johnson & Johnson News

5 Relatively Safe And Cheap Dividend Stocks To Invest In - February 2023

5 Relatively Safe And Cheap Dividend Stocks To Invest In - February 2023

Seeking Alpha

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms. It's always a good idea to keep your wish list ready by separating the wheat from the chaff.

3 Defensive Stocks to Buy If You Think the Market Is Headed Lower

3 Defensive Stocks to Buy If You Think the Market Is Headed Lower

InvestorPlace

As we kick off a new year, investing in defensive stocks certainly appears to be in focus for many investors. Following a brutal 2022, many aggressive investors were taught a lesson by Mr.

Johnson & Johnson Press Releases

Johnson & johnson to participate in the cowen 43 rd annual healthcare conference

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj) will participate in the cowen 43 rd annual healthcare conference on tuesday, march 7 th, at the boston marriott copley place, boston, ma. joseph j. wolk, executive vice president and chief financial officer will represent the company in a session scheduled at 11 10 a. m. ( eastern time).

Federal appellate court rejects controversial j& j ploy to dodge talc cancer lawsuits

NAC hawati law group ovarian cancer victims DES erve day in court philadelphia , jan. 30, 2023 prnewswire trial lawyers with the NAC hawati law group praised a ruling by the u. s. court of appeals for the third CIR cuit rejecting johnson & johnson' s ( nyse jnj) use of a controversial bankruptcy ploy to shed more than 38,000 lawsuits filed by women who developed ovarian cancer after using j& j' s talc based products. the jan. 30 ruling means j& j can be held accountable for its failure to warn consumers about known cancer risks associated with talc based products like johnson' s baby powder, said trial lawyer majed NAC hawati , founder of dallas based NAC hawati law group.

Federal appellate court rejects controversial j& j ploy to dodge talc cancer lawsuits

NAC hawati law group ovarian cancer victims DES erve day in court philadelphia , jan. 30, 2023 prnewswire trial lawyers with the NAC hawati law group praised a ruling by the u. s. court of appeals for the third CIR cuit rejecting johnson & johnson' s ( nyse jnj) use of a controversial bankruptcy ploy to shed more than 38,000 lawsuits filed by women who developed ovarian cancer after using j& j' s talc based products. the jan. 30 ruling means j& j can be held accountable for its failure to warn consumers about known cancer risks associated with talc based products like johnson' s baby powder, said trial lawyer majed NAC hawati , founder of dallas based NAC hawati law group.

Johnson & johnson reports q4 and full year 2022 results

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj) today announced results for fourth quarter and full year 2022. “ our full year 2022 results reflect the continued strength and stability of our three business segments, DES pite MAC roeconomic challenges,” said joaquin duato, chairman of the board and chief executive officer. “ i am inspired by our employees who make a difference in the health and lives of people around the world every day. as we look ahead to 2023, johnson & johnson is well positioned to drive near term growth, while also investing strategically to deliver long term value.”

Johnson & johnson to participate in the svb securities global biopharma conference

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj) will participate in the svb securities global biopharma conference on wednesday, february 15 th. biljana naumovic, worldwide vice president, oncology and peter lebowitz, global therapeutic head, oncology will represent the company in a virtual session scheduled at 1 00 p. m. ( eastern time).

Johnson & johnson completes acquisition of abiomed

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj), the world' s largest, most diversified healthcare products company, today announced it has completed its acquisition of abiomed, inc. abiomed is now part of johnson & johnson and will operate as a standalone business within johnson & johnson' s medtech segment.

Steel dynamics set to join s& p 500; super micro computer to join s& p midcap 400

New york , dec. 19, 2022 prnewswire s& p midcap 400 constituent steel dynamics inc. ( nasd stld) will replace abiomed inc. ( nasd abmd) in the s& p 500 and super micro computer inc. ( nasd smci) will replace steel dynamics in the s& p midcap 400 effective prior to the opening of trading on thursday, DEC ember 22. s& p 500 constituent johnson & johnson ( nyse jnj) is acquiring abiomed in a deal expected to close soon pending final conditions.

Johnson & johnson announces extension of abiomed tender offer to DEC ember 21, 2022

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj), the world' s largest, most diversified healthcare products company, today announced that athos merger sub, inc. (“ offeror”), a wholly owned subsidiary of johnson & johnson, has extended the expiration date of its offer ( the “ offer”) to acquire all of the outstanding shares of common stock of abiomed, inc. ( nasdaq abmd), for an upfront payment of 380.00 per share in cash, plus one non tradeable contingent value right entitling the holder to receive up to 35.00 per share in cash if certain commercial and CLI NIC al milestones are achieved.

Johnson & johnson to participate in the 41 st annual j. p. morgan healthcare conference

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj) will participate in the 41 st annual j. p. morgan healthcare conference on monday, january 9 th, at the westin st. francis in san francisco, ca. joaquin duato, chairman elect of the board and chief executive officer will represent the company in a session scheduled at 12 45 p. m. ( eastern time).

Johnson & johnson names ceo joaquin duato as chairman of the board

New brunswick, n. j. ( business wire ) johnson & johnson ( nyse jnj) today announced that its board of directors has elected chief executive officer, mr. joaquin duato, to assume the additional position of chairman, effective in january 2023. mr. duato succeeds mr. alex gorsky, who will step down from his role as executive chairman following a brief transitional period.